Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Cyclacel Pharmaceuticals, Inc. (CYCC) Posts Q4 Loss of 19c/Share
March 25, 2014 4:05 PM EDTCyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q4 EPS of ($0.19), $0.14 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $299 thousand versus the consensus estimate of $90 thousand.
For earnings history and earnings-related data on Cyclacel Pharmaceuticals, Inc. (CYCC) click here.... More
